Cancer Research UK, London Research Institute, Lincoln's Inn Fields Laboratories, London WC2A 3PX, UK.
Mol Oncol. 2010 Jun;4(3):192-208. doi: 10.1016/j.molonc.2010.04.004. Epub 2010 Apr 18.
Breast cancer is a heterogeneous disease, comprising multiple entities associated with distinctive histological and biological features, clinical presentations and behaviours and responses to therapy. Microarray-based technologies have unravelled the molecular underpinning of several characteristics of breast cancer, including metastatic propensity and histological grade, and have led to the identification of prognostic and predictive gene expression signatures. Furthermore, a molecular taxonomy of breast cancer based on transcriptomic analysis has been proposed. However, microarray studies have primarily focused on invasive ductal carcinomas of no special type. Owing to the relative rarity of special types of breast cancer, information about the biology and clinical behaviour of breast cancers conveyed by histological type has not been taken into account. Histological special types of breast cancer account for up to 25% of all invasive breast cancers. Recent studies have provided direct evidence of the existence of genotypic-phenotypic correlations. For instance, secretory carcinomas of the breast consistently harbour the t(12;15) translocation that leads to the formation of the ETV6-NTRK3 fusion gene, adenoid cystic carcinomas consistently display the t(6;9) MYB-NFIB translocation and lobular carcinomas consistently show inactivation of the CDH1 gene through multiple molecular mechanisms. Furthermore, histopathological and molecular analysis of tumours from conditional mouse models has provided direct evidence for the causative role of specific genes in the genesis of specific histological special types of breast cancer. Here we review the associations between the molecular taxonomy of breast cancer and histological special types, discuss the possible origins of the heterogeneity of breast cancer and propose an approach for the identification of novel therapeutic targets based on the study of histological special types of breast cancer.
乳腺癌是一种异质性疾病,包含多个实体,具有独特的组织学和生物学特征、临床表现和行为以及对治疗的反应。基于微阵列的技术揭示了乳腺癌的几个特征的分子基础,包括转移倾向和组织学分级,并导致了预后和预测基因表达特征的识别。此外,还提出了基于转录组分析的乳腺癌分子分类法。然而,微阵列研究主要集中在非特殊类型的浸润性导管癌上。由于特殊类型乳腺癌的相对罕见性,组织学类型所传达的乳腺癌生物学和临床行为信息尚未被考虑在内。特殊类型的乳腺癌占所有浸润性乳腺癌的 25%。最近的研究提供了存在基因型-表型相关性的直接证据。例如,乳腺分泌性癌始终存在导致 ETV6-NTRK3 融合基因形成的 t(12;15)易位,腺样囊性癌始终显示 t(6;9)MYB-NFIB 易位,而小叶癌始终通过多种分子机制显示 CDH1 基因失活。此外,条件性小鼠模型肿瘤的组织病理学和分子分析为特定基因在特定组织学特殊类型乳腺癌的发生中的因果作用提供了直接证据。在这里,我们回顾了乳腺癌的分子分类法与组织学特殊类型之间的关联,讨论了乳腺癌异质性的可能起源,并提出了一种基于对组织学特殊类型乳腺癌的研究来识别新治疗靶点的方法。